 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

StockNews.com started coverage on shares of Eiger BioPharmaceuticals (NASDAQ:EIGR  Free Report) in a research report sent to investors on Friday morning. The firm issued a sell rating on the...

Eiger BioPharmaceuticals (NASDAQ:EIGR) Coverage Initiated at StockNews.com

Eiger BioPharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update Eiger BioPharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update...

Eiger BioPharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

StockNews.com initiated coverage on shares of Eiger BioPharmaceuticals (NASDAQ:EIGR  Free Report) in a research report sent to investors on Tuesday morning. The brokerage issued a sell rating...

Eiger BioPharmaceuticals (NASDAQ:EIGR) Coverage Initiated by Analysts at StockNews.com

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Eiger BioPharmaceuticals down 27% at 51c per share after resumption of trade

Eiger BioPharmaceuticals trading resumes

Eiger BioPharmaceuticals to resume trading at 4:35 pm ET

Eiger to Discontinue Phase 3 LIMT-2 Trial of Peginterferon Lambda in Patients with Chronic Hepatitis Delta Eiger to Discontinue Phase 3 LIMT-2 Trial of Peginterferon Lambda in Patients with Chronic...

Eiger to Discontinue Phase 3 LIMT-2 Trial of Peginterferon Lambda in Patients with Chronic Hepatitis Delta

Eiger BioPharmaceuticals to Present at H.C. Wainwright 25th Annual Global Investment Conference Eiger BioPharmaceuticals to Present at H.C. Wainwright 25th Annual Global Investment Conference PR...

Eiger BioPharmaceuticals to Present at H.C. Wainwright 25th Annual Global Investment Conference

Eiger BioPharmaceuticals (NASDAQ:EIGR  Free Report) had its price objective lowered by Citigroup from $4.00 to $3.00 in a report published on Tuesday, Benzinga reports. The brokerage currently...

Eiger BioPharmaceuticals (NASDAQ:EIGR) PT Lowered to $3.00

Citi analyst Yigal Nochomovitz maintained a Buy rating on Eiger Biopharmaceuticals (EIGR Research Report) yesterday and set a price target of $3.... Citi analyst Yigal Nochomovitz maintained a Buy rating on Eiger Biopharmaceuticals (EIGR  Re...

Citi Sticks to Their Buy Rating for Eiger Biopharmaceuticals (EIGR)

Eiger BioPharmaceuticals, Inc. engages in the development and commercialization of foundational therapies for Hepatitis Delta Virus. It is also developing avexitide as a treatment for Post-Bariatric Hypoglycemia. The company was founded by David A. Cory and Glenn S. Jeffrey on November 6, 2008 and is headquartered in Palo Alto, CA.

Market Cap	$14.2M
Volume (M)	347.00
52-Wk High	$2.98
52-Wk Low	$0.21

EIGR Eiger BioPharmaceuticals Inc

About

Feed

News

Sentiment

Earnings

Fundamentals